How the ‘holy grail’ weight loss pill became a reality, and what comes next
Oral GLP-1 weight-loss drugs have arrived: Novo Nordisk released an oral Wegovy formulation and Eli Lilly’s oral GLP‑1 candidate orforglipron is expected to seek approval imminently. Developers overcame major formulation challenges that made pills harder to create than injectables, driving heavy investment and prompting debate about pricing, access, and market dynamics.
Why it mattersFDA decision on Eli Lilly's orforglipron will reshape US GLP‑1 market dynamics.
People Mentioned
Alex Hogan